curasan is launching Spinevisc® hyaluronic acid (HA) for the treatment of facet joint arthrosis.
Spinevisc will allow the company to address new target customer groups such as neuroradiologists and interventional pain therapists, as well as spine surgeons.
Other HA-based products from curasan include Curavisc for the treatment of arthritic joints ex-U.S. and CERASORB bone replacement material.
Source: curasan AG
curasan is launching Spinevisc® hyaluronic acid (HA) for the treatment of facet joint arthrosis.
Spinevisc will allow the company to address new target customer groups such as neuroradiologists and interventional pain therapists, as well as spine surgeons.
Other HA-based products from curasan include Curavisc for the treatment of arthritic...
curasan is launching Spinevisc® hyaluronic acid (HA) for the treatment of facet joint arthrosis.
Spinevisc will allow the company to address new target customer groups such as neuroradiologists and interventional pain therapists, as well as spine surgeons.
Other HA-based products from curasan include Curavisc for the treatment of arthritic joints ex-U.S. and CERASORB bone replacement material.
Source: curasan AG
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





